MarketCapExport financials
Vanda Pharmaceuticals (VNDA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Vanda Pharmaceuticals Balance Sheet 2025-2008 | VNDA
Brief balance sheet overview of Vanda Pharmaceuticals
The review uses the five latest available annual reports between 2021 and 2025.
Assets fell from $593.8 million to $488.9 million. This may reflect either deliberate optimization or a reduction in business scale.
Asset growth of -17.7% came with a +82% rise in liabilities. Financial leverage became more prominent.
The equity-to-assets ratio is 66.9%, compared with 85% five periods ago. The balance sheet has a substantial internal cushion.
Cash exceeds interest-bearing debt, producing net debt of -$78.6 million. The balance sheet therefore carries a net cash position.
Cash equals 17.4% of the balance sheet, compared with 8.9% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$394.8 million. It should be assessed alongside historical profits and capital distributions.
Conclusion
Vanda Pharmaceuticals 's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Vanda Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-78.6 M | -96.7 M | -126 M | -124 M | -40.2 M | -48 M | -30.5 M | -61 M | -33.6 M | -40.4 M | -50.8 M | -60.9 M | -64.8 M | -88.8 M | -87.9 M | - | - | - |
Long Term Debt |
4.08 M | 3.15 M | 7.01 M | 8.81 M | 10.1 M | 11.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.15 M | 2.46 M | 2.4 M | 2.33 M | 2.31 M | 2.12 M | 2.15 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 13.3 M | 3.69 M | 3.68 M | 28.7 M | 28.7 M | 3.1 M | 66.4 M | 93.3 M | 118 M | - | - | - |
Total Current Liabilities |
145 M | 100 M | 87.7 M | 91.4 M | 74.4 M | 65.9 M | 59.5 M | 53 M | 70.4 M | 50.3 M | 51.3 M | 7.79 M | 32.9 M | 32.3 M | 31.6 M | 31 M | - | - |
Total Liabilities |
162 M | 118 M | 104 M | 107 M | 88.9 M | 80.2 M | 72.8 M | 56.7 M | 74 M | 79 M | 80 M | 10.9 M | 99.2 M | 126 M | 149 M | 175 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | 174 K | 26.8 M | 26.8 M | 27.2 M | 26.8 M | - | - |
Retained Earnings |
-395 M | -174 M | -155 M | -158 M | -164 M | - | -221 M | -336 M | -361 M | -346 M | -328 M | -288 M | -311 M | -291 M | -263 M | -254 M | - | - |
Total Assets |
489 M | 656 M | 648 M | 634 M | 594 M | 533 M | 484 M | 332 M | 205 M | 210 M | 213 M | 172 M | 143 M | 135 M | 183 M | 213 M | - | - |
Cash and Cash Equivalents |
84.9 M | 102 M | 136 M | 135 M | 52.6 M | 61.6 M | 45.1 M | 61 M | 33.6 M | 40.4 M | 50.8 M | 60.9 M | 64.8 M | 88.8 M | 87.9 M | 42.6 M | 205 M | 39.1 M |
Book Value |
327 M | 539 M | 545 M | 527 M | 505 M | 453 M | 411 M | 275 M | 131 M | 131 M | 133 M | 161 M | 44.1 M | 9.9 M | 33.5 M | 37.7 M | - | - |
Total Shareholders Equity |
327 M | 539 M | 545 M | 527 M | 505 M | 453 M | 411 M | 275 M | 131 M | 131 M | 133 M | 161 M | 44.1 M | 9.9 M | 33.5 M | 37.7 M | 23 M | 46 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Vanda Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.18 M | 3.78 M | 2.81 M | 3.08 M | 2.95 M | 3.15 M | 5.49 M | 6 M | - | 7.01 M | 7.47 M | 7.94 M | 8.39 M | 8.81 M | 8.9 M | - | 9.66 M | 10.1 M | 10.5 M | 10.7 M | 11.1 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
192 M | 153 M | 135 M | 138 M | 121 M | 118 M | 104 M | 109 M | - | 104 M | 98.5 M | 102 M | 109 M | 107 M | 106 M | - | 101 M | 88.9 M | 86.4 M | 86.4 M | 75.6 M | 80.2 M | 80.2 M | 80.2 M | 80.2 M | 72.8 M | 72.8 M | 72.8 M | 72.8 M | 56.7 M | 56.7 M | 56.7 M | 56.7 M | 74 M | 74 M | 74 M | 74 M | 79 M | 79 M | 79 M | 79 M | 80 M | 80 M | 80 M | 80 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 99.2 M | 99.2 M | 99.2 M | 99.2 M | 126 M | 126 M | 126 M | 126 M | 149 M | 149 M | 149 M | 149 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 174 K | 31.2 M | 31.1 M | 31.1 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M |
Retained Earnings |
-506 M | -443 M | -254 M | -231 M | -204 M | -174 M | -169 M | -164 M | - | -155 M | -153 M | -153 M | -155 M | -158 M | -165 M | - | -171 M | -164 M | -171 M | -179 M | -189 M | -197 M | -197 M | -197 M | -197 M | -221 M | -221 M | -221 M | -221 M | -336 M | -336 M | -336 M | -336 M | -361 M | -361 M | -361 M | -361 M | -346 M | -346 M | -346 M | -346 M | -328 M | -328 M | -328 M | -328 M | -288 M | -288 M | -288 M | -288 M | -308 M | -308 M | -308 M | -308 M | -291 M | -291 M | -291 M | -291 M | -263 M | -263 M | -263 M | -263 M |
Total Assets |
412 M | 434 M | 601 M | 625 M | 632 M | 656 M | 645 M | 651 M | - | 648 M | 642 M | 642 M | 645 M | 634 M | 622 M | - | 604 M | 594 M | 580 M | 568 M | 543 M | 533 M | 533 M | 533 M | 533 M | 484 M | 484 M | 484 M | 484 M | 332 M | 332 M | 332 M | 332 M | 205 M | 205 M | 205 M | 205 M | 210 M | 210 M | 210 M | 210 M | 213 M | 213 M | 213 M | 213 M | 172 M | 172 M | 172 M | 172 M | 143 M | 143 M | 143 M | 143 M | 135 M | 135 M | 135 M | 135 M | 183 M | 183 M | 183 M | 183 M |
Cash and Cash Equivalents |
55.9 M | 54 M | 70 M | 81 M | 112 M | 102 M | 100 M | 103 M | 125 M | 136 M | 183 M | 150 M | 354 M | 135 M | 49.4 M | 58.2 M | 66.9 M | 52.1 M | 50.5 M | 57.2 M | 72.1 M | 61 M | 61 M | 61 M | 61 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 61 M | 61 M | 61 M | 61 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 40.4 M | 40.4 M | 40.4 M | 40.4 M | 50.8 M | 50.8 M | 50.8 M | 50.8 M | 60.9 M | 60.9 M | 60.9 M | 60.9 M | 64.8 M | 64.8 M | 64.8 M | 64.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 87.9 M | 87.9 M | 87.9 M | 87.9 M |
Book Value |
220 M | 281 M | 466 M | 486 M | 511 M | 539 M | 541 M | 543 M | - | 545 M | 543 M | 540 M | 536 M | 527 M | 516 M | - | 502 M | 505 M | 493 M | 481 M | 468 M | 453 M | 453 M | 453 M | 453 M | 411 M | 411 M | 411 M | 411 M | 275 M | 275 M | 275 M | 275 M | 131 M | 131 M | 131 M | 131 M | 131 M | 131 M | 131 M | 131 M | 133 M | 133 M | 133 M | 133 M | 161 M | 161 M | 161 M | 161 M | 44.1 M | 44.1 M | 44.1 M | 44.1 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M |
Total Shareholders Equity |
220 M | 281 M | 466 M | 486 M | 511 M | 539 M | 541 M | 543 M | 544 M | 545 M | 543 M | 540 M | 536 M | 527 M | 516 M | 509 M | 502 M | 505 M | 493 M | 481 M | 468 M | 453 M | 453 M | 453 M | 453 M | 411 M | 411 M | 411 M | 411 M | 275 M | 275 M | 275 M | 275 M | 131 M | 131 M | 131 M | 131 M | 131 M | 131 M | 131 M | 131 M | 133 M | 133 M | 133 M | 133 M | 161 M | 161 M | 161 M | 161 M | 44.1 M | 44.1 M | 44.1 M | 44.1 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Vanda Pharmaceuticals , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
